Neuroscience
Dementia Praecox
100%
Antipsychotic
57%
Major Depressive Disorder
39%
Typical Antipsychotic
39%
Alzheimer's Disease
30%
Meta-Analysis
26%
Treatment-Resistant Schizophrenia
25%
Clozapine
22%
Antidepressant
18%
Bipolar Disorder
17%
Positron Emission Tomography
17%
Depression
16%
Behavior (Neuroscience)
15%
Electroconvulsive Therapy
14%
Positive Syndrome
14%
Pervasive Developmental Disorder
14%
Negative Syndrome
14%
Olanzapine
13%
Receptor Occupancy
13%
Mild Cognitive Impairment
12%
Dopamine Receptor D2
12%
Transcranial Magnetic Stimulation
12%
Glutamic Acid
11%
Randomized Controlled Trial
11%
Risperidone
11%
Cognitive Function
11%
Nuclear Magnetic Resonance Spectroscopy
10%
Amyloid
9%
Mood Disorder
9%
Gray Matter
9%
Placebo
8%
Fluorine-18
7%
Cognitive Behavioral Therapy
7%
Functional Connectivity
7%
Positron Emission Tomography
7%
Anterior Cingulate Cortex
7%
Functional Magnetic Resonance Imaging
7%
Treatment of Schizophrenia
7%
Cognitive Disorders
7%
Psychoactive Drug
7%
Striatum
6%
Dorsolateral Prefrontal Cortex
6%
Magnetic Resonance Imaging
6%
Eicosanoid Receptor
6%
Psychiatry
6%
Longitudinal Study
6%
Hippocampus
5%
Clinical Dementia Rating
5%
Benzodiazepine
5%
Electroencephalography
5%
Cingulate Cortex
5%
Mental Disorder
5%
Anxiety Disorder
5%
Treatment-Resistant Depression
5%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
62%
Typical Antipsychotic
43%
Clozapine
26%
Symptom
26%
Risperidone
19%
Disease
18%
Olanzapine
17%
Randomized Controlled Trial
14%
Antidepressant
13%
Polypharmacy
12%
Receptor
12%
Dopamine Receptor D2
11%
Treatment-Resistant Schizophrenia
11%
Major Depression
11%
Psychotropic Agent
11%
Bipolar Disorder
10%
Negative Syndrome
10%
Positive Syndrome
10%
Side Effect
9%
Pharmacokinetics
9%
Cross-Sectional Study
8%
Remission
8%
Pharmacotherapy
7%
Adverse Event
7%
Cohort Study
6%
Alzheimer's Disease
6%
Monotherapy
6%
Extrapyramidal Symptoms
6%
Schizophrenia
6%
Observational Study
6%
Aripiprazole
5%
Mood Disorder
5%
Placebo
5%
Clinical Trial
5%
Benzodiazepine
5%
Combination Therapy
5%
Keyphrases
Antipsychotics
19%
Patients with Schizophrenia
16%
Schizophrenia
16%
Meta-analysis
13%
Japan
11%
Treatment-resistant Schizophrenia
9%
Clozapine
9%
Systematic Meta-analysis
7%
Olanzapine
7%
Antipsychotic Dose
6%
Neurometabolites
6%
Risperidone
6%
Schizophrenia Treatment
5%
Randomized Controlled Trial
5%
Confidence Interval
5%
Major Depressive Disorder
5%
Proton Magnetic Resonance Spectroscopy
5%